e8381a92.5379.4ece.8414.230d0f0026e1
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 63
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.620
- MYC_TARGETS_V2+0.590
- G2M_CHECKPOINT+0.560
- MYC_TARGETS_V1+0.540
- INTERFERON_ALPHA_RESPONSE+0.400
- INTERFERON_GAMMA_RESPONSE+0.380
- ALLOGRAFT_REJECTION+0.340
- MTORC1_SIGNALING+0.340
- GLYCOLYSIS+0.330
- UNFOLDED_PROTEIN_RESPONSE+0.270
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.470
- NOTCH_SIGNALING-0.430
- MYOGENESIS-0.360
- ESTROGEN_RESPONSE_EARLY-0.310
- TGF_BETA_SIGNALING-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.290
- BILE_ACID_METABOLISM-0.260
- CHOLESTEROL_HOMEOSTASIS-0.260
- COAGULATION-0.260
- KRAS_SIGNALING_DN-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-00203 | — | cohortA1 | 0.888 |
| 2 | TCGA-AR-A1AI-01A-11R-A12P-07 | — | E | 0.869 |
| 3 | 58c2404d-b213-4a7f-a8fc-11081a88091b | — | — | 0.866 |
| 4 | SRR8518289 | — | E | 0.865 |
| 5 | TCGA-ZF-A9RF-01A-11R-A38B-07 | — | — | 0.862 |
| 6 | TCGA-E2-A1II-01A-11R-A144-07 | — | E | 0.860 |
| 7 | c63f3f74-14fa-4a9e-9925-30b0f5da7dd9 | — | — | 0.850 |
| 8 | TCGA-AN-A0AJ-01A-11R-A00Z-07 | — | C | 0.846 |
| 9 | TCGA-C8-A1HM-01A-12R-A137-07 | — | C | 0.845 |
| 10 | TCGA-18-3416-01A-01R-0980-07 | — | cohortSQ2 | 0.836 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.620 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.590 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.560 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.540 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.380 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.340 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.330 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.270 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.240 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.230 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| HYPOXIA | 0.170 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.150 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |